TY  -  
T1  - TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade 
SN  -  /  
UR  - http://hdl.handle.net/10138/313935 
T3  -  
A1  - Cervera-Carrascon, V.; Siurala, M.; Santos, J. M.; Havunen, R.; Tähtinen, S.; Karell, P.; Sorsa, S.; Kanerva, A.; Hemminki, A. 
A2  -  
PB  -  
Y1  - 2018 
LA  - eng 
AB  - Releasing the patient's immune system against their own malignancy by the use of checkpoint inhibitors is delivering promising results. However, only a subset of patients currently benefit from them. One major limitation of these therapies relates to the inability of T cells to detect or penetrate into the tumor resulting in unresponsiveness to checkpoint inhibition. Virotherapy is an attractive tool for enabling checkpoint inhibitors as viruses are naturally recognized by innate defense element... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - Immunotherapy; Virotherapy; Immunovirotherapy; Checkpoint blockade; Adoptive cell therapy; Adenovirus; Melanoma; Solid tumors; anti-PD1; T cell therapy; Adoptive T cell therapies; Models of immunostimulation; Therapeutic antibodies; T-CELL THERAPY; NECROSIS-FACTOR-ALPHA; ONCOLYTIC ADENOVIRUS; INFILTRATING LYMPHOCYTES; TALIMOGENE LAHERPAREPVEC; CANCER-IMMUNOTHERAPY; INHIBITORY RECEPTORS; IDENTITY CRISIS; TUMOR; MELANOMA; 3122 Cancers 
N1  -   
PP  -  
ER  -